<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of cytomegalovirus infection in lung transplant recipients</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of cytomegalovirus infection in lung transplant recipients</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of cytomegalovirus infection in lung transplant recipients</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin Zamora, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emily A Blumberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1635497404"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cytomegalovirus (CMV), a betaherpesvirus, is an important cause of morbidity and mortality in lung transplant recipients [<a href="#rid1">1</a>]. It is among the most common infections in lung transplant recipients, closely following bacterial pneumonia [<a href="#rid2">2,3</a>]. While the development and availability of potent antiviral agents have decreased CMV-related mortality, there is a growing body of evidence that the indirect effects of CMV may be equally important or even more important than its direct effects of tissue injury and infection [<a href="#rid3">3</a>]. CMV-induced immunosuppression may lead to infection with other opportunistic organisms. In addition, CMV infection and disease have been associated with acute and chronic rejection (chronic lung allograft dysfunction) [<a href="#rid4">4-6</a>]. The approach to the diagnosis and treatment of CMV infections in lung transplant recipients continues to evolve as molecular diagnostic techniques and antiviral therapies advance.</p><p>The prevention of CMV infection in lung transplant recipients will be discussed here. The clinical manifestations, diagnosis, and treatment of CMV infection in lung transplant recipients and infectious complications due to agents other than CMV are discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1413.html" rel="external">"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1407.html" rel="external">"Tuberculosis in solid organ transplant candidates and recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">"Fungal infections following lung transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H1635497410"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Primary CMV infection is acquired through close physical contact involving direct inoculation with infected cells or body fluids. Following primary infection, CMV infection persists for life. Population studies document a gradual increase in CMV seropositivity through young adulthood. Although there is considerable variability, more than one half of adults in the United States have serologic evidence of previous infection. (See  <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults"</a>.)</p><p>CMV infection following transplantation can be acquired in one of several ways [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Transmission from the donor organ from a CMV-seropositive donor</p><p class="bulletIndent1"><span class="glyph">●</span>Transfusion of blood products from a CMV-seropositive blood donor</p><p class="bulletIndent1"><span class="glyph">●</span>Reactivation of latent infection in a seropositive recipient</p><p class="bulletIndent1"><span class="glyph">●</span>Close physical contact with a CMV-infected individual (if the recipient is CMV naïve)</p><p></p><p class="headingAnchor" id="H3938461360"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>CMV infection and disease are not synonymous terms; not all patients with infection develop overt clinical disease [<a href="#rid7">7-10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CMV infection</strong> is characterized by virus isolation or detection of viral proteins (antigens) or nucleic acid in any body fluid or tissue specimen regardless of symptoms or signs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CMV disease</strong> is characterized by evidence of CMV infection with attributable symptoms or signs; CMV disease may manifest as either a viral syndrome with fever, malaise, leukopenia, neutropenia, atypical lymphocytosis, and/or thrombocytopenia or as tissue-invasive disease.</p><p></p><p class="headingAnchor" id="H75824932"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The most important risk factor for CMV infection and disease in lung transplant recipients is CMV serologic status, with seronegative recipients of seropositive organs (CMV D+/R-) having the highest risk. Immunosuppressive regimens can also play a major role on the impact of CMV replication in lung transplant recipients. In particular, the use of antilymphocyte antibodies as induction therapy or for the treatment of steroid-resistant rejection has been strongly associated with the development of CMV disease in certain recipients (CMV D+/R-, D-/R+, or D+/R+) [<a href="#rid11">11,12</a>]. High doses of glucocorticoids have also been identified as a risk factor for CMV disease [<a href="#rid13">13</a>].</p><p>Certain gene polymorphisms involved in innate immunity (toll-like receptor 2<em> </em>[<em>TLR2</em>], <em>TLR4</em>, mannose-binding lectin, and interferon L3/4 [<em>IFNL3</em>/<em>4</em>]) are associated with an increased incidence of CMV infection or disease following transplantation [<a href="#rid14">14-17</a>]. Evolving research suggests that short telomere defects impair CMV immunity and are risk factors for CMV infection in lung transplant recipients [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H1635497416"><span class="h2">Serologic status</span><span class="headingEndMark"> — </span>The overall likelihood of developing CMV infection or disease in lung transplant recipients ranges from 54 to 92 percent in patients without prophylaxis [<a href="#rid19">19-21</a>]. The most important risk factor for CMV infection and disease is organ donor (D) and recipient (R) serostatus, with CMV D+/R- recipients at the highest risk followed by CMV D+/R+; CMV D-/R+ are at lower risk [<a href="#rid19">19,20</a>]. (See <a class="local">'Universal prophylaxis'</a> below.)</p><p>The lung has been identified as a major site of CMV latency and recurrence [<a href="#rid22">22</a>]. Lung transplantation is associated with the transfer of a larger CMV load than other solid organs and, as a result, the risk of CMV infection and disease is greater than in other solid organ transplant recipients. Therefore, most lung transplant programs employ aggressive preventive measures for all D+ or R+ lung transplant recipients.</p><p>Serologic status impacts the risk of CMV infection as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>D+/R-</strong> − CMV D+/R- recipients are at the greatest risk for CMV, with infection occurring in up to 71 percent of recipients, with 85 percent of infected individuals developing disease (in the absence of prophylaxis). The case-fatality rate of patients with CMV disease has approached 22 percent but, due to the availability of potent antiviral agents, mortality has been substantially reduced [<a href="#rid3">3</a>]. In a single-center series, the survival rate for CMV-mismatched recipients was similar to that for other donor-recipient serologic combinations [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>D-/R+ and D+/R+</strong> − Early studies have suggested that CMV infection develops in approximately 58 and 69 percent of CMV D-/R+ and D+/R+ recipients, respectively [<a href="#rid24">24</a>]. The risk is higher in the latter group because reactivation as well as superinfection with a new virus strain can occur. However, more recent reports in the era of <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> prophylaxis found that the risk of infection or disease is much less in D-/R+ and D+/R+ patients, particularly in D-/R+ recipients [<a href="#rid25">25,26</a>]. In one study, during the 180-day period following six months of CMV prophylaxis, the incidence of CMV infection or disease was 6 percent in D-/R+ recipients and 34 percent in D+/R+ recipients [<a href="#rid25">25</a>]. Progression from CMV infection to disease is less common in these recipients who have immunity to CMV, occurring in one-fourth to one-third of cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>D-/R-</strong> − The risk of CMV infection is lowest in seronegative recipients of seronegative donor lungs (CMV D-/R-).</p><p></p><p class="headingAnchor" id="H1635497428"><span class="h1">DIAGNOSTIC TESTS</span><span class="headingEndMark"> — </span>Serologic testing to assess the risk of CMV infection prior to transplantation as well as the use of appropriate diagnostic tests for the detection of active CMV infection following transplantation are essential for the management of lung transplant recipients.</p><p class="headingAnchor" id="H5471661"><span class="h2">Pretransplant serologic testing</span><span class="headingEndMark"> — </span>The recipient should be tested for CMV antibodies prior to transplantation, and the donor should be tested before or at the time of transplantation in order to ascertain the need for postoperative prophylaxis. Seronegative recipients should also be tested on the day of transplantation prior to going to the operating room to correctly assign risk. Only CMV immunoglobulin (Ig)G should be tested for rather than IgM or a combination of IgM and IgG since false-positive IgM results might reduce the specificity of screening [<a href="#rid7">7,8,27-29</a>]. Serology should <strong>not</strong> be used to diagnose active CMV infection or disease in lung transplant recipients [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/8291.html" rel="external">"Overview of diagnostic tests for cytomegalovirus infection", section on 'Serology'</a>.)</p><p class="headingAnchor" id="H695482"><span class="h2">Post-transplant monitoring</span><span class="headingEndMark"> — </span>Quantitative polymerase chain reaction (PCR; ie, viral load testing) is the preferred test for monitoring for CMV reactivation following transplantation [<a href="#rid7">7</a>]. In general, a quantitative PCR assay that is calibrated to the World Health Organization (WHO) international standard (with results reported in international units/mL) should be used. Calibration to the international standard reduces some but not all variability among different assays and different institutional testing practices [<a href="#rid30">30,31</a>]. Because sample types (plasma versus whole blood), deoxyribonucleic acid (DNA) extraction techniques, and other factors still vary among testing centers, it is important to use the same assay while monitoring an individual patient over time. (See  <a class="medical medical_review" href="/z/d/html/8291.html" rel="external">"Overview of diagnostic tests for cytomegalovirus infection", section on 'Molecular assays'</a>.)</p><p>Historically, the CMV pp65 antigenemia assay was commonly used to diagnose CMV reactivation posttransplantation, but this has now been largely supplanted by quantitative PCR. Serology should <strong>not</strong> be used to diagnose active CMV infection or disease in lung transplant recipients. (See  <a class="medical medical_review" href="/z/d/html/8291.html" rel="external">"Overview of diagnostic tests for cytomegalovirus infection"</a> and  <a class="medical medical_review" href="/z/d/html/8305.html" rel="external">"Approach to the diagnosis of cytomegalovirus infection"</a> and  <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients", section on 'Diagnosis'</a>.)</p><p>In general, patients who are receiving antiviral prophylaxis do not require routine viral load monitoring. By contrast, patients who are being managed with a pre-emptive approach should undergo routine viral load monitoring. (See <a class="local">'Universal prophylaxis'</a> below and <a class="local">'Pre-emptive therapy'</a> below.)</p><p class="headingAnchor" id="H164450485"><span class="h2">CMV-specific immunity</span><span class="headingEndMark"> — </span>Assays for assessing CMV-specific T cell responses have been developed to predict which patients are at increased risk for CMV disease following transplantation and are used at some transplant centers outside the United States [<a href="#rid7">7</a>]. Tests include a QuantiFERON assay, an ELISpot assay, major histocompatibility complex multimer staining assays, and intracellular cytokine staining assays. Such assays may be particularly useful in combination with viral load monitoring in high-risk (eg, CMV D+/R-) solid organ transplant recipients following the completion of antiviral prophylaxis.</p><p>As an example, a QuantiFERON CMV assay has been evaluated for assessing CMV-specific cell-mediated immunity in whole-blood specimens by measuring interferon-gamma levels following in vitro stimulation with CMV antigens [<a href="#rid32">32</a>]. In a prospective multicenter cohort study, 127 CMV D+/R- solid organ transplant recipients (including 14 lung transplant recipients) receiving antiviral prophylaxis for a median of 98 days underwent testing at the end of prophylaxis and one and two months later. At 12 months, patients with a positive result had a significantly lower risk of CMV disease than patients with a negative or indeterminate result (6 versus 22 versus 58 percent, respectively). Similar results have been reported in other studies [<a href="#rid33">33-35</a>].</p><p>In a cohort study of 263 lung transplant recipients (59 D+/R-, 204 R+), extending the standard 5-month duration of CMV prophylaxis to 11 months for patients who did not have a detectable CMV-immune response based on QuantiFERON testing (at the 5-month mark) was associated with reduced CMV infection (43 versus 60 percent) [<a href="#rid36">36</a>]. Therapy was most often extended in D+/R- recipients who are less likely to develop an immune response and are at the highest risk for CMV infection. Thus, it is unclear whether the risk reduction was attributable to QuantiFERON testing or extending prophylaxis in the highest risk group.</p><p class="headingAnchor" id="H1635497466"><span class="h1">PREVENTION OF DISEASE</span><span class="headingEndMark"> — </span>Because CMV causes considerable morbidity and mortality and has been identified as a risk factor for chronic rejection in lung transplant recipients, there has been intense interest in prevention [<a href="#rid7">7,19,24,37</a>]. Two strategies have been used:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Universal prophylaxis</strong> of recipients at high risk for infection (ie, all but CMV donor-negative, recipient-negative [CMV D-/R-] recipients). Oral <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> is currently the most commonly used drug for prophylaxis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pre-emptive treatment</strong> of recipients with infection in order to abort the development of disease. Using this approach, patients are monitored for CMV in the blood at regular intervals (ie, weekly), and oral <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> is initiated when viral replication has reached a certain assay threshold defined at each institution.</p><p></p><p>Given the high risk of CMV disease in lung transplant recipients, we favor antiviral prophylaxis over pre-emptive therapy in all lung transplant recipients who are CMV seropositive or who received an organ from a CMV-seropositive donor (CMV D+/R+, D-/R+, D+/R-) [<a href="#rid19">19</a>]. The use of antiviral prophylaxis in seropositive lung transplant recipients is also endorsed by the 2018 international consensus guidelines on the management of CMV in solid organ transplantation [<a href="#rid38">38</a>].</p><p>Support for the use of universal prophylaxis is based on a substantial body of published evidence in lung transplant recipients [<a href="#rid7">7,8,19</a>]. There is a paucity of evidence on the safety and efficacy of pre-emptive therapy compared with that of universal prophylaxis in lung transplant recipients. Furthermore, few studies have directly compared universal prophylaxis to pre-emptive therapy in this population.</p><p>Several studies have compared pre-emptive and prophylactic strategies in solid organ transplant recipients, but the majority of patients in these studies have been renal and liver transplant recipients, and few lung transplant recipients have been included. The results of these studies might not apply to lung transplant recipients, who have a higher risk of CMV infection and disease than renal transplant recipients. These studies are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/105281.html" rel="external">"Prevention of cytomegalovirus disease in kidney transplant recipients", section on 'Preventive strategies'</a>.)</p><p class="headingAnchor" id="H572572"><span class="h2">Universal prophylaxis</span><span class="headingEndMark"> — </span>Antiviral prophylaxis (either alone or in combination with CMV immune globulin) is the most widely used prophylactic approach for lung transplant recipients [<a href="#rid39">39,40</a>]. Oral <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> and intravenous <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> are the drugs of choice for CMV prophylaxis. <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">Acyclovir</a> is ineffective for the prevention of CMV infection after lung transplantation [<a href="#rid41">41-43</a>].</p><p class="headingAnchor" id="H81755994"><span class="h3">Approach to prophylaxis</span><span class="headingEndMark"> — </span>The following recommendations are based upon published guidelines and on a randomized trial described below [<a href="#rid7">7,8,19,38,44</a>]. However, the approach to prophylaxis chosen for each patient depends upon protocols developed at each transplant center.</p><p>In the immediate posttransplant period, patients who are seropositive for CMV or who received an organ from a seropositive donor (CMV D+/R+, D-/R+, D+/R-) should receive intravenous <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> 5 mg/kg once daily, with dose adjustment for renal insufficiency. Once the patient is absorbing oral medications or at hospital discharge, ganciclovir can be switched to oral <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> 900 mg once daily, with dose adjustment for renal insufficiency.</p><p>The 2018 international consensus guidelines recommend 6 to 12 months of prophylaxis for CMV D+/R- lung transplant recipients [<a href="#rid8">8,38</a>]. For CMV D+/R+ and D-/R+ lung transplant recipients, a minimum of six months of prophylaxis is recommended. The decision on duration of prophylaxis depends upon several factors, including the patient's risk of CMV reactivation, development of drug toxicity, and the feasibility of frequent viral load monitoring. (See <a class="local">'Pre-emptive therapy'</a> below.)</p><p><a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">Valganciclovir</a> prophylaxis is preferred over pre-emptive therapy for patients who are seropositive for CMV or who received an organ from a seropositive donor who are receiving antilymphocyte antibodies, high doses of glucocorticoids, or other potent immunosuppressives used for the treatment of rejection, since such patients are at increased risk of CMV infection. Prophylaxis should be continued for one to three months after the antirejection therapy has been completed [<a href="#rid7">7,8</a>]. (See <a class="local">'Risk factors'</a> above.)</p><p>Use of adjunctive <a class="drug drug_general" data-topicid="9315" href="/z/d/drug information/9315.html" rel="external">cytomegalovirus immune globulin</a> (CytoGam) is controversial. While some experts do add CMV immune globulin to antiviral therapy for high-risk patients (eg, CMV D+/R-, D+/R+, D-/R+; particularly in those receiving a lymphocyte-depleting agent), data supporting this approach are limited. (See <a class="local">'CMV immune globulin'</a> below.)</p><p class="headingAnchor" id="H155783438"><span class="h3">Valganciclovir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">Valganciclovir</a>, a <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> prodrug with excellent oral bioavailability, has become the drug of choice for the prophylactic management of CMV infection after lung transplantation [<a href="#rid8">8,19,45</a>]. It has proven efficacy in heart, kidney, and kidney-pancreas transplantation compared with oral ganciclovir [<a href="#rid46">46</a>]. One randomized trial and several nonrandomized studies have also shown that valganciclovir is effective for the prevention of CMV infection and disease in lung transplant recipients [<a href="#rid44">44,45,47,48</a>].</p><p>The randomized trial included 136 lung transplant recipients with positive donor or recipient CMV serology who received oral <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> (900 mg orally once daily, with dose adjustment for renal insufficiency) for three months, followed by an additional nine months of either valganciclovir or placebo; the following findings were noted [<a href="#rid44">44</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Those who received 12 months of <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> prophylaxis were less likely to develop CMV disease than those who received 3 months of valganciclovir prophylaxis (4 versus 32 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals who received 12 months of prophylaxis were also less likely to develop CMV infection (10 versus 64 percent) and less likely to have invasive disease (2 versus 21 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There were no significant differences between the groups in the incidence of non-CMV opportunistic infections or acute rejection episodes following randomization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no difference in the incidence of ganciclovir-resistant CMV infection, and there was a similar incidence of CMV disease during the 6 months following study completion between those who received 12 months of prophylaxis and those who received 3 months of prophylaxis (3 versus 2 percent).</p><p></p><p>In a subset analysis that included 38 patients who were followed for a mean of 3.9 years, those who received 12 months of prophylaxis continued to have a reduced risk of CMV viremia or pneumonitis compared with those who received 3 months of prophylaxis (12 versus 55 percent; hazard ratio 0.13, 95% CI 0.03-0.61) [<a href="#rid49">49</a>]. White blood cell, neutrophil, and platelet counts were similar between the two groups, demonstrating that the longer duration of prophylaxis did not increase the risk of hematologic toxicity.</p><p>Based on these results, many experts favor continuing <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> prophylaxis for 12 months following lung transplantation in patients who are CMV seropositive or who received an organ from a CMV-seropositive donor (CMV D+/R+, D-/R+, D+/R-), but particularly in CMV D+/R- patients, who are at the highest risk for CMV reactivation. Some experts prefer to give prophylaxis for six months followed by a pre-emptive approach with frequent CMV load monitoring in CMV D+/R+ or D-/R+ patients. In a retrospective study that evaluated the risk of late-onset CMV infections during the 180-day period following the discontinuation of CMV prophylaxis (at six months posttransplant) in lung or heart-lung transplant recipients, the proportion of patients with CMV infection or disease differed substantially depending on serostatus [<a href="#rid25">25</a>]. Forty-nine percent of CMV D+/R- patients developed CMV infection or disease (infection: 29 percent; disease: 20 percent), compared with 34 percent of CMV D+/R+ patients (infection: 23 percent; disease: 11 percent), and only 6 percent of CMV D-/R+ patients (infection: 6 percent; disease: 0 percent).</p><p>When used for prophylaxis, <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> should be dosed at 900 mg orally once daily, with dose adjustment for renal insufficiency. It is important to give appropriate doses of valganciclovir and <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a>, since inadequate dosing may reduce efficacy and lead to resistance, whereas supratherapeutic dosing may lead to toxicity [<a href="#rid7">7,50,51</a>].</p><p>The toxicity profile of <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> is similar to that of its parent compound, <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a>. Hematologic suppression, in particular leukopenia (including neutropenia), appears to be the most significant and common adverse event associated with these agents. When leukopenia occurs, dose reduction of valganciclovir should be avoided, given the risk of promoting resistance [<a href="#rid7">7</a>]. Patients should be evaluated for other potential causes of leukopenia (eg, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>). The addition of granulocyte colony-stimulating factor (G-CSF) should be considered before discontinuing valganciclovir. (See <a class="local">'Ganciclovir'</a> below and  <a class="medical medical_review" href="/z/d/html/8342.html" rel="external">"Ganciclovir and valganciclovir: An overview", section on 'Bone marrow suppression'</a>.)</p><p class="headingAnchor" id="H2592775"><span class="h3">Ganciclovir</span><span class="headingEndMark"> — </span>As noted above, <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> has replaced <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> as the drug of choice for CMV prophylaxis. (See <a class="local">'Valganciclovir'</a> above.)</p><p>A three-month course of intravenous <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> has been shown to reduce the occurrence of CMV illness in all donor-recipient serologic combinations at risk [<a href="#rid52">52,53</a>]. In contrast, a short course of low-dose intravenous ganciclovir during the first three postoperative weeks failed to prevent CMV illness in a small group of CMV recipient-negative, donor-positive lung transplant recipients [<a href="#rid54">54</a>]. Ganciclovir inhibits viral replication but does not eradicate latent infection. Thus, ganciclovir prophylaxis is effective while it is being administered but does not confer long-term protection [<a href="#rid52">52,53</a>]. However, the delay in onset of CMV infection that it produces is advantageous because the disease is less frequent and less difficult to manage when the recipient has recuperated from surgery, the effects of cytolytic induction have waned, maintenance immunosuppression is less intense, and the highest-risk period for acute rejection has passed. Nevertheless, there is still a substantial rate of CMV infection and disease in individuals who receive only three months of antiviral prophylaxis [<a href="#rid44">44</a>]. A 12-month course of antiviral prophylaxis with oral <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> has been shown to be superior to a three-month course, as discussed below. (See <a class="local">'Valganciclovir'</a> above.)</p><p>Experience with prophylactic oral <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> is limited because oral bioavailability is very low. Some benefit has been suggested in CMV-mismatched recipients when used after an initial period of intravenous ganciclovir [<a href="#rid55">55</a>]. However, oral ganciclovir is no longer routinely available in the United States, and its use has been supplanted by oral <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a>, as discussed in the following section.</p><p>When intravenous <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> is used for prophylaxis, it should be dosed at 5 mg/kg once daily, with dose adjustment for renal insufficiency.</p><p>As discussed above, hematologic suppression, in particular leukopenia (including neutropenia), appears to be the most significant and common adverse event associated with <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> and <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a>. When leukopenia occurs, dose reduction of ganciclovir should be avoided, given the risk of promoting resistance [<a href="#rid7">7</a>]. Patients should be evaluated for other potential causes of leukopenia (eg, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>). The addition of G-CSF should be considered before discontinuing ganciclovir or valganciclovir. (See  <a class="medical medical_review" href="/z/d/html/8342.html" rel="external">"Ganciclovir and valganciclovir: An overview", section on 'Bone marrow suppression'</a> and  <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H46530082"><span class="h3">CMV immune globulin</span><span class="headingEndMark"> — </span>Use of adjunctive <a class="drug drug_general" data-topicid="9315" href="/z/d/drug information/9315.html" rel="external">cytomegalovirus immune globulin</a> (CytoGam) is controversial. While some experts do add CMV immune globulin to antiviral therapy for high-risk patients (eg, CMV D+/R-, D+/R+, D-/R+; particularly in those receiving a lymphocyte-depleting agent), data supporting this approach are limited [<a href="#rid45">45</a>]. A retrospective study compared prophylaxis with <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> plus CMV immune globulin in a group of lung and heart-lung recipients to prophylaxis with ganciclovir alone in a group of historical controls at the same center [<a href="#rid56">56</a>]. In this analysis, freedom from CMV disease, freedom from bronchiolitis obliterans syndrome (chronic rejection), and survival were greater in the first three years after transplantation in the group that received the combination of CMV immune globulin and ganciclovir. Adequately powered randomized trials measuring the additive benefit of CMV immune globulin in the lung transplant population have not yet been performed.</p><p>Because efficacy data are limited, many experts do not favor the addition of CMV immunoglobulin to treatment regimens; this approach is no longer recommended in the 2018 international consensus guidelines [<a href="#rid7">7</a>].</p><p>CMV immune globulin has <strong>no</strong> role for CMV prophylaxis in lung transplant recipients when given alone [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H3540445356"><span class="h3">Letermovir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="115632" href="/z/d/drug information/115632.html" rel="external">Letermovir</a> (a novel inhibitor of viral terminase subunit pUL56) is not routinely used for prophylaxis in lung transplant recipients. While this agent is US Food and Drug Administration approved for prevention of CMV disease in hematopoietic cell transplant recipients and kidney transplant recipients, its efficacy has not been well studied in lung transplant recipients [<a href="#rid58">58,59</a>]. While one small single-center review suggests that rates of breakthrough viremia are high during letermovir prophylaxis [<a href="#rid60">60</a>], findings from another retrospective review of heart and lung transplant recipients suggest that the agent may be an effective alternative when <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> cannot be tolerated (eg, for profound valganciclovir-induced myelosuppression). In a review of 41 heart and lung transplant recipients who used letermovir for primary or secondary prophylaxis (when other agents could not be tolerated), low-level viremia was detected in 15 percent of cases; one case of clinically significant viremia occurred. Although these findings are encouraging, in most cases, letermovir was initiated late in the post-transplantation period when the likelihood of active CMV infection was lower. Thus, until further data are available, we continue to use valganciclovir as the preferred prophylactic agent [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H1635497496"><span class="h2">Pre-emptive therapy</span><span class="headingEndMark"> — </span>Using the pre-emptive approach, patients are monitored frequently (ie, weekly) with a CMV load or antigenemia assay, and antiviral therapy is initiated when viral replication has reached a certain assay threshold defined at each institution [<a href="#rid7">7,8</a>]. For asymptomatic CMV viremia, oral <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> has supplanted intravenous <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> as the drug of choice [<a href="#rid38">38</a>].</p><p>The pre-emptive approach is predicated upon a convenient, reliable surveillance test that identifies infection prior to the emergence of disease [<a href="#rid38">38</a>]. The most widely used screening test is the quantitative CMV polymerase chain reaction (PCR) assay (ie, viral load testing). CMV antigenemia assays can also detect CMV DNA in blood but has been largely supplanted by PCR.</p><p>Evidence of CMV replication usually precedes overt clinical findings, and therapy given at this point can potentially abort the development of CMV disease [<a href="#rid20">20</a>]. Pre-emptive therapy has some potential advantages over universal prophylaxis. Because only recipients with infection receive pre-emptive therapy, fewer patients are treated for a shorter duration. The net decrease in drug usage and exposure could decrease costs, drug-related toxicity, catheter-related complications, and potentially the evolution of drug-resistant strains of CMV [<a href="#rid62">62,63</a>]. However, pre-emptive therapy is not used commonly in lung transplant recipients during the early posttransplant period, given the high risk of CMV infection in such patients and the limited data about its efficacy in this population. In one trial of renal transplant recipients, prophylaxis was more effective than pre-emptive therapy for preventing CMV disease and resulted in higher rates of graft survival [<a href="#rid64">64</a>].</p><p>Given the lack of data regarding the pre-emptive approach and the high risk of CMV infection and disease in lung transplant recipients, we do not recommend the pre-emptive approach during the early posttransplant period. Instead, a pre-emptive approach can be used after the period of prophylaxis has ended. Protocols for pre-emptive therapy should be developed and validated at each transplant center [<a href="#rid7">7</a>]. Recommendations for viral load monitoring are discussed above. (See <a class="local">'Post-transplant monitoring'</a> above.)</p><p>When indicated, treatment should consist of either <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> 900 mg orally twice daily (for mild to moderate disease) or intravenous <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> 5 mg/kg every 12 hours (less common and reserved for severe disease). Treatment should be continued for a minimum of two weeks and until a single viral load is undetectable or less than the lower quantifiable limits (ie, &lt;200 international units/mL) when a highly sensitive assay is used or when two consecutive viral loads drawn one week apart are undetectable when using less sensitive assays [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients", section on 'Pre-emptive therapy for asymptomatic viremia'</a>.)</p><p class="headingAnchor" id="H50073781"><span class="h2">Other approaches</span></p><p class="headingAnchor" id="H50073823"><span class="h3">Blood products</span><span class="headingEndMark"> — </span>CMV-seronegative (CMV D-/R-) lung transplant recipients should receive only CMV-negative or leukoreduced blood products to decrease the risk of transfusion-related CMV transmission [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">"Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'CMV-seronegative red cells'</a> and  <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">"Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Pre-storage leukoreduction'</a>.)</p><p class="headingAnchor" id="H6819183"><span class="h3">Vaccination</span><span class="headingEndMark"> — </span>Several CMV vaccines have been developed, but none are available for clinical use [<a href="#rid7">7,65,66</a>]. Use of a live-attenuated CMV Towne strain vaccine in seronegative patients prior to renal transplantation with seropositive organs did not decrease the overall incidence of CMV infection or disease [<a href="#rid67">67</a>]. However, severe cases of CMV disease were less common among vaccinated versus placebo-treated patients.</p><p class="headingAnchor" id="H2057509385"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109354.html" rel="external">"Society guideline links: Cytomegalovirus in solid organ transplant recipients"</a>.)</p><p class="headingAnchor" id="H4591324"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Important background</strong> – Cytomegalovirus (CMV) remains an important cause of morbidity and mortality in lung transplant recipients. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transmission routes</strong> – CMV infection following transplantation can be acquired in one of several ways (see <a class="local">'Epidemiology'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>By transmission with the donor organ from a CMV-seropositive donor</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>By transfusion of blood products from a CMV-seropositive blood donor</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>By reactivation of latent infection in a CMV-seropositive recipient</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>By close physical contact with a CMV-infected individual</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – CMV infection is characterized by virus isolation or detection of viral proteins (antigens) or nucleic acid in any body fluid or tissue specimen regardless of symptoms. CMV disease is characterized by evidence of CMV infection with attributable symptoms; CMV disease may manifest as either a viral syndrome with fever, malaise, leukopenia, neutropenia, atypical lymphocytosis, and/or thrombocytopenia or as tissue-invasive disease. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – The most important risk factor for CMV infection and disease in lung transplant recipients is CMV serologic status, with seronegative recipients of seropositive organs (CMV D+/R-) having the highest risk. The use of antilymphocyte antibodies as induction therapy or for the treatment of steroid-resistant rejection is associated with an increase in CMV replication and the development of CMV disease in seropositive recipients. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to prophylaxis</strong> – We recommend universal prophylaxis against CMV with oral <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> rather than pre-emptive therapy for all lung transplant recipients who are CMV seropositive or who received an organ from a seropositive donor (CMV D+/R+, D-/R+, D+/R-) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early posttransplantation</strong> – In the immediate posttransplant period, patients should receive intravenous <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a> 5 mg/kg once daily, with dose adjustment for renal insufficiency  (<a class="graphic graphic_table graphicRef78763" href="/z/d/graphic/78763.html" rel="external">table 1</a>). Once the patient is absorbing oral medications or at hospital discharge, ganciclovir can be switched to oral <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> 900 mg once daily, with dose adjustment for renal insufficiency. (See <a class="local">'Approach to prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of prophylaxis</strong> – Some experts favor continuing CMV prophylaxis for 12 months following transplantation in lung transplant recipients who are CMV D+/R- and for 6 to 12 months in CMV D+/R+ and D-/R+ patients. The decision of which duration to give to patients who are CMV D+/R+ or D-/R+ depends upon several factors, including the patient's risk of CMV reactivation, development of drug toxicity, and the feasibility of frequent viral load monitoring. (See <a class="local">'Approach to prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other indications for prophylaxis</strong> – We recommend CMV prophylaxis with oral <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> for lung transplant recipients who are CMV seropositive or who received an organ from a seropositive donor (CMV D+/R+, D-/R+, D+/R-) with rejection who are receiving antilymphocyte antibodies or high doses of glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Prophylaxis should be continued for one to three months after the antirejection therapy has been completed. (See <a class="local">'Approach to prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pre-emptive therapy</strong> – An alternative to CMV prophylaxis is pre-emptive therapy, in which antiviral therapy is initiated if viral replication has reached a certain assay threshold defined at each institution. However, pre-emptive therapy is not used commonly during the early posttransplant period in lung transplant recipients, given the high risk of CMV infection in such patients and the limited data about its efficacy in this population. A pre-emptive approach is more often used after the period of prophylaxis has ended. (See <a class="local">'Pre-emptive therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive CMV </strong><strong>immune globulin</strong> – Use of adjunctive <a class="drug drug_general" data-topicid="9315" href="/z/d/drug information/9315.html" rel="external">cytomegalovirus immune globulin</a> (CytoGam) is controversial. Some experts favor adding CMV immune globulin to antiviral therapy for selected high-risk patients. However, data supporting this approach are limited and it is no longer recommended by international consensus guidelines. (See <a class="local">'CMV immune globulin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CMV-negative or leukoreduced blood products</strong> – CMV seronegative (CMV D-/R-) lung transplant recipients should receive only CMV-negative or leukoreduced blood products to decrease the risk of transfusion-related CMV transmission. (See <a class="local">'Blood products'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004; 17:357.</a></li><li><a class="nounderline abstract_t">Balfour HH Jr. Cytomegalovirus: the troll of transplantation. Arch Intern Med 1979; 139:279.</a></li><li><a class="nounderline abstract_t">Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant 2004; 4:1219.</a></li><li><a class="nounderline abstract_t">Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21:297.</a></li><li><a class="nounderline abstract_t">Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002; 21:271.</a></li><li><a class="nounderline abstract_t">Tamm M, Aboyoun CL, Chhajed PN, et al. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004; 170:1120.</a></li><li><a class="nounderline abstract_t">Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96:333.</a></li><li><a class="nounderline abstract_t">Razonable RR, Humar A, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:93.</a></li><li><a class="nounderline abstract_t">Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Dis 2017; 64:87.</a></li><li><a class="nounderline abstract_t">Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34:1094.</a></li><li><a class="nounderline abstract_t">Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992; 53:68.</a></li><li><a class="nounderline abstract_t">Jamil B, Nicholls KM, Becker GJ, Walker RG. Influence of anti-rejection therapy on the timing of cytomegalovirus disease and other infections in renal transplant recipients. Clin Transplant 2000; 14:14.</a></li><li><a class="nounderline abstract_t">Cope AV, Sabin C, Burroughs A, et al. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176:1484.</a></li><li><a class="nounderline abstract_t">Kang SH, Abdel-Massih RC, Brown RA, et al. Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis 2012; 205:639.</a></li><li><a class="nounderline abstract_t">Cervera C, Lozano F, Saval N, et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 2007; 83:1493.</a></li><li><a class="nounderline abstract_t">Manuel O, Pascual M, Trendelenburg M, Meylan PR. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 2007; 83:359.</a></li><li><a class="nounderline abstract_t">Manuel O, Wójtowicz A, Bibert S, et al. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J Infect Dis 2015; 211:906.</a></li><li><a class="nounderline abstract_t">Popescu I, Mannem H, Winters SA, et al. Impaired Cytomegalovirus Immunity in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients with Short Telomeres. Am J Respir Crit Care Med 2019; 199:362.</a></li><li><a class="nounderline abstract_t">Zamora MR, Davis RD, Leonard C, CMV Advisory Board Expert Committee. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 2005; 80:157.</a></li><li><a class="nounderline abstract_t">Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis 1993; 147:1017.</a></li><li><a class="nounderline abstract_t">Duncan AJ, Dummer JS, Paradis IL, et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991; 10:638.</a></li><li><a class="nounderline abstract_t">Balthesen M, Messerle M, Reddehase MJ. Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol 1993; 67:5360.</a></li><li><a class="nounderline abstract_t">Glanville AR, Valentine VG, Aboyoun CL, Malouf MA. CMV mismatch is not a risk factor for survival or severe bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2004; 23:S43.</a></li><li><a class="nounderline abstract_t">Zamora MR. Controversies in lung transplantation: management of cytomegalovirus infections. J Heart Lung Transplant 2002; 21:841.</a></li><li><a class="nounderline abstract_t">Schoeppler KE, Lyu DM, Grazia TJ, et al. Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis? Am J Transplant 2013; 13:376.</a></li><li><a class="nounderline abstract_t">Hammond SP, Martin ST, Roberts K, et al. Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis. Transpl Infect Dis 2013; 15:163.</a></li><li><a class="nounderline abstract_t">Seed CR, Piscitelli LM, Maine GT, et al. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood. Transfusion 2009; 49:134.</a></li><li><a class="nounderline abstract_t">Weber B, Fall EM, Berger A, Doerr HW. Screening of blood donors for human cytomegalovirus (HCMV) IgG antibody with an enzyme immunoassay using recombinant antigens. J Clin Virol 1999; 14:173.</a></li><li><a class="nounderline abstract_t">Lazzarotto T, Brojanac S, Maine GT, Landini MP. Search for cytomegalovirus-specific immunoglobulin M: comparison between a new western blot, conventional western blot, and nine commercially available assays. Clin Diagn Lab Immunol 1997; 4:483.</a></li><li><a class="nounderline abstract_t">Hayden RT, Sun Y, Tang L, et al. Progress in Quantitative Viral Load Testing: Variability and Impact of the WHO Quantitative International Standards. J Clin Microbiol 2017; 55:423.</a></li><li><a class="nounderline abstract_t">Jones S, Webb EM, Barry CP, et al. Commutability of Cytomegalovirus WHO International Standard in Different Matrices. J Clin Microbiol 2016; 54:1512.</a></li><li><a class="nounderline abstract_t">Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013; 56:817.</a></li><li><a class="nounderline abstract_t">Westall GP, Cristiano Y, Levvey BJ, et al. A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation. Transplantation 2019; 103:1005.</a></li><li><a class="nounderline abstract_t">Kumar D, Chin-Hong P, Kayler L, et al. A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients. Am J Transplant 2019; 19:2505.</a></li><li><a class="nounderline abstract_t">Donadeu L, Revilla-López E, Jarque M, et al. CMV-Specific Cell-Mediated Immunity Predicts a High Level of CMV Replication After Prophylaxis Withdrawal in Lung Transplant Recipients. J Infect Dis 2021; 224:526.</a></li><li><a class="nounderline abstract_t">Gardiner BJ, Lee SJ, Robertson AN, et al. Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients. J Heart Lung Transplant 2022; 41:1258.</a></li><li><a class="nounderline abstract_t">Bando K, Paradis IL, Komatsu K, et al. Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg 1995; 109:49.</a></li><li><a class="nounderline abstract_t">Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation 2018; 102:900.</a></li><li><a class="nounderline abstract_t">Le Page AK, Jager MM, Kotton CN, et al. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation 2013; 95:1455.</a></li><li><a class="nounderline abstract_t">Zuk DM, Humar A, Weinkauf JG, et al. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation 2010; 90:672.</a></li><li><a class="nounderline abstract_t">Paradis IL, Williams P. Infection after lung transplantation. Semin Respir Infect 1993; 8:207.</a></li><li><a class="nounderline abstract_t">Duncan SR, Paradis IL, Dauber JH, et al. Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients. Am Rev Respir Dis 1992; 146:1213.</a></li><li><a class="nounderline abstract_t">Bailey TC, Ettinger NA, Storch GA, et al. Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med 1993; 95:273.</a></li><li><a class="nounderline abstract_t">Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152:761.</a></li><li><a class="nounderline abstract_t">Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4:1635.</a></li><li><a class="nounderline abstract_t">Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611.</a></li><li><a class="nounderline abstract_t">Jaksch P, Zweytick B, Kerschner H, et al. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant 2009; 28:670.</a></li><li><a class="nounderline abstract_t">Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008; 46:831.</a></li><li><a class="nounderline abstract_t">Finlen Copeland CA, Davis WA, Snyder LD, et al. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant 2011; 30:990.</a></li><li><a class="nounderline abstract_t">Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 2000; 97:8039.</a></li><li><a class="nounderline abstract_t">McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001; 61:1153.</a></li><li><a class="nounderline abstract_t">Duncan SR, Grgurich WF, Iacono AT, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994; 150:146.</a></li><li><a class="nounderline abstract_t">Gutiérrez CA, Chaparro C, Krajden M, et al. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest 1998; 113:924.</a></li><li><a class="nounderline abstract_t">Bailey TC, Trulock EP, Ettinger NA, et al. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis 1992; 165:548.</a></li><li><a class="nounderline abstract_t">Palmer SM, Grinnan DC, Diane Reams B, et al. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Clin Transplant 2004; 18:179.</a></li><li><a class="nounderline abstract_t">Valantine HA, Luikart H, Doyle R, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001; 72:1647.</a></li><li><a class="nounderline abstract_t">Kruger RM, Paranjothi S, Storch GA, et al. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients. J Heart Lung Transplant 2003; 22:754.</a></li><li class="breakAll">PREVYMIS (letermovir) Tablets and PREVYMIS (letermovir) Injection. US Food and Drug Administration, 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000TOC.cfm (Accessed on February 09, 2021). (Accessed on September 08, 2023).</li><li class="breakAll">Patient information on PREVYMIS letermovir tablets. US Food and Drug Information, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209939s012,209940s011lbl.pdf (Accessed on September 08, 2023).</li><li><a class="nounderline abstract_t">Aryal S, Katugaha SB, Cochrane A, et al. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients. Transpl Infect Dis 2019; 21:e13166.</a></li><li><a class="nounderline abstract_t">Saullo JL, Baker AW, Snyder LD, et al. Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis. J Heart Lung Transplant 2022; 41:508.</a></li><li><a class="nounderline abstract_t">Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356:645.</a></li><li><a class="nounderline abstract_t">Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185:20.</a></li><li><a class="nounderline abstract_t">Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8:975.</a></li><li><a class="nounderline abstract_t">Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4:725.</a></li><li><a class="nounderline abstract_t">Aldoss I, La Rosa C, Baden LR, et al. Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial. Ann Intern Med 2020; 172:306.</a></li><li><a class="nounderline abstract_t">Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994; 58:1176.</a></li></ol></div><div id="topicVersionRevision">Topic 8313 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15241082" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/218511" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cytomegalovirus: the troll of transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15268722" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cytomegalovirus and lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11897517" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11834356" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk factors for bronchiolitis obliterans: a systematic review of recent publications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15297275" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23896556" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23465003" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cytomegalovirus in solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27682069" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11914998" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Definitions of cytomegalovirus infection and disease in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1310173" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10693630" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Influence of anti-rejection therapy on the timing of cytomegalovirus disease and other infections in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9395358" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22219347" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17565323" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The influence of innate immunity gene receptors polymorphisms in renal transplant infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17297414" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25301956" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30088779" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Impaired Cytomegalovirus Immunity in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients with Short Telomeres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16041258" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8385429" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1659899" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cytomegalovirus infection and survival in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8394453" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Lungs are a major organ site of cytomegalovirus latency and recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : CMV mismatch is not a risk factor for survival or severe bronchiolitis obliterans syndrome after lung transplantation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12163083" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Controversies in lung transplantation: management of cytomegalovirus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23205887" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23230972" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18954407" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10614854" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Screening of blood donors for human cytomegalovirus (HCMV) IgG antibody with an enzyme immunoassay using recombinant antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9220169" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Search for cytomegalovirus-specific immunoglobulin M: comparison between a new western blot, conventional western blot, and nine commercially available assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27852673" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Progress in Quantitative Viral Load Testing: Variability and Impact of the WHO Quantitative International Standards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27030491" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Commutability of Cytomegalovirus WHO International Standard in Different Matrices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23196955" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30247316" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30768834" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33245359" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : CMV-Specific Cell-Mediated Immunity Predicts a High Level of CMV Replication After Prophylaxis Withdrawal in Lung Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35868965" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7815807" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29596116" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23640298" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20581765" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : An international survey of cytomegalovirus management practices in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8016481" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Infection after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1332558" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8396320" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20547904" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15367218" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15023154" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19560694" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18269330" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21489817" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10859361" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11465876" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8025741" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554627" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1311352" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15016133" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11726825" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873543" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873543" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873543" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31487755" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35031206" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10968438" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11756977" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18261177" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15567122" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32040960" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7992358" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
